N-Cyclopropyltryptamine
Pharmaceutical compound
From Wikipedia, the free encyclopedia
N-Cyclopropyltryptamine (NcPT) is a monoamine oxidase inhibitor (MAOI) of the tryptamine family related to N-methyltryptamine (NMT).[1][2][3]
 | |
| Clinical data | |
|---|---|
| Other names | NcPT |
| Drug class | Monoamine oxidase inhibitor (MAOI) |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C13H16N2 |
| Molar mass | 200.285 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It is a potent MAOI, with greater activity than pargyline (56–67% inhibition at 100 nM versus 41% inhibition at 100 nM, respectively).[3][4][1] The drug markedly potentiates the behavioral effects of 5-hydroxytryptophan (5-HTP) in rodents.[3] In addition, it produces tremors, hypolocomotion, motor incoordination, and vasodilation in rodents.[3] NcPT has also been reported to have antihyperglycemic activity.[1] The drug has not been assessed in terms of psychedelic-related behavioral effects.[2]
The chemical synthesis of NcPT has been described.[1] Some notable derivatives of NcPT include 5-MeO-NcPT, 7-MeO-NcPT, 5,6-DiMeO-NcPT, and 6,7-DiMeO-NcPT, which showed MAOI activity similarly to NcPT.[1][2][3][5][6] Some other derivatives include the psychedelic designer drugs N-methyl-N-cyclopropyltryptamine (McPT), 4-HO-McPT, and 4-AcO-McPT.
NcPT was first described in the scientific literature by 1975.[3]